A DIETARY supplement marketed to support weight loss and appetite control in New Zealand, Calocurb, has been reported to the NZ Centre for Adverse Reactions Monitoring for an association with an anaphylactic event requiring hospitalisation - medsafe.govt.nz.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 May 18